Cargando…

HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents

Hepatitis C virus (HCV) infection is a systemic disorder that frequently associates with extrahepatic manifestations, including nephropathies. Cryoglobulinemia is a typical extrahepatic manifestation of HCV infection that often involves kidneys with a histological pattern of membranoproliferative gl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Angeletti, Andrea, Cantarelli, Chiara, Cravedi, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376251/ https://www.ncbi.nlm.nih.gov/pubmed/30800660 http://dx.doi.org/10.3389/fmed.2019.00020

Ejemplares similares

Immune-Monitoring Disease Activity in Primary Membranous Nephropathy
por: Cravedi, Paolo, et al.
Publicado: (2019)

HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
por: La Manna, Gaetano
Publicado: (2018)

HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals
por: Rice, Donald P., et al.
Publicado: (2016)

The ‘Viennese epidemic’ of acute HCV in the era of direct‐acting antivirals
por: Chromy, David, et al.
Publicado: (2022)

Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era
por: Stevenson, Heather L., et al.
Publicado: (2016)

Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation
por: Martin, Natasha K., et al.
Publicado: (2016)

Direct-Acting Antiviral Agents for HCV-Associated Glomerular Disease and the Current Evidence
por: Fabrizi, Fabrizio, et al.
Publicado: (2019)

Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination
por: Virlogeux, Victor, et al.
Publicado: (2017)

Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients
por: Armando, Calogero, et al.
Publicado: (2019)

Association of Renal Function and Direct-Acting Antiviral Agents for HCV: A Network Meta-Analysis
por: Kao, Chih-Chin, et al.
Publicado: (2018)

Liver Fibrosis Regression and Associated Factors in HCV Patients Treated with Direct-Acting Antiviral Agents
por: Abu-Freha, Naim, et al.
Publicado: (2023)

Cardiac Toxicity Associated with HCV Direct Antiviral Agents
por: Ucciferri, Claudio, et al.
Publicado: (2018)

Efficacy and Safety of Glecaprevir/Pibrentasvir in HCV Patients With Previous Direct-Acting Antiviral Therapy Failures: A Meta-Analysis
por: Shen, Chao, et al.
Publicado: (2020)

Erratum to “Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients”
por: Calogero, Armando, et al.
Publicado: (2019)

Efficacy and Safety of Direct-Acting Antivirals in Kidney Transplantation From HCV-Viremic Donors to Negative Recipients: A Meta-Analysis
por: Feng, Zepei, et al.
Publicado: (2022)

Recent Information on Pan-Genotypic Direct-Acting Antiviral Agents for HCV in Chronic Kidney Disease
por: Fabrizi, Fabrizio, et al.
Publicado: (2022)

B-cell Clonality in HCV-Induced Patients Treated with Oral Direct-Acting Antiviral Agents
por: Waly, Basma, et al.
Publicado: (2023)

“Raising HOPE”: Improved Outcomes for HIV/HCV-coinfected Liver Transplant Recipients in the Direct-acting Antiviral Era
por: Cotter, Thomas G., et al.
Publicado: (2021)

Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis
por: Kawagishi, Naoki, et al.
Publicado: (2018)

Geno2pheno([HCV]) – A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral Agents
por: Kalaghatgi, Prabhav, et al.
Publicado: (2016)

Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs
por: Minosse, Claudia, et al.
Publicado: (2021)

HCC in the Era of Direct-Acting Antiviral Agents (DAAs): Surgical and Other Curative or Palliative Strategies in the Elderly
por: Brozzetti, Stefania, et al.
Publicado: (2021)

Screening and surveillance of oesophageal varices in patients with HCV‐positive liver cirrhosis successfully treated by direct‐acting antiviral agents
por: Ciancio, Alessia, et al.
Publicado: (2022)

Transplantation of HCV Viremic Livers into HCV Viremic Recipients Followed by Direct-acting Antiviral Therapy
por: Kapila, Nikhil, et al.
Publicado: (2019)

Changing Trends of Cirrhotic and Noncirrhotic Hepatocellular Carcinoma in the Era of Directly-Acting Antiviral Agents
por: Mathur, Karan, et al.
Publicado: (2021)

Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data
por: Chen, Zhi-wei, et al.
Publicado: (2016)

Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA)
por: Dold, L., et al.
Publicado: (2019)

HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients
por: Brochado-Kith, Óscar, et al.
Publicado: (2021)

Hepatitis C Screening and Treatment Program in Hungarian Prisons in the Era of Direct Acting Antiviral Agents
por: Werling, Klára, et al.
Publicado: (2022)

Direct Binding of Ledipasvir to HCV NS5A: Mechanism of Resistance to an HCV Antiviral Agent
por: Kwon, Hyock Joo, et al.
Publicado: (2015)

Resistant-Associated Substitutions Do Not Affect HCV RNA and HCV Core Antigen Clearance During Direct-Acting Antiviral Agent Treatment in a Real-World Setting
por: Chen, Hongyu, et al.
Publicado: (2022)

Genetic Barrier to Direct Acting Antivirals in HCV Sequences Deposited in the European Databank
por: Kliemann, Dimas Alexandre, et al.
Publicado: (2016)

Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV
por: Patel, Sonia Vibhakar, et al.
Publicado: (2020)

Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment
por: Dash, Srikanta, et al.
Publicado: (2020)

Telomere Length Increase in HIV/HCV-Coinfected Patients with Cirrhosis after HCV Eradication with Direct-Acting Antivirals (†)
por: Molina-Carrión, Silvia, et al.
Publicado: (2020)

Baseline Plasma Metabotype Correlates With Direct-Acting Antiviral Therapy Nonresponse for HCV in HIV–HCV Coinfected Patients
por: Tripathi, Gaurav, et al.
Publicado: (2022)

Hepatocellular Carcinoma Recurrence in HCV Patients Treated with Direct Antiviral Agents
por: Sanduzzi-Zamparelli, Marco, et al.
Publicado: (2019)

Direct antiviral agents for HCV infection and hepatocellular carcinoma: facts and FADs
por: Serio, Ilaria, et al.
Publicado: (2019)

Complement in Non-Antibody-Mediated Kidney Diseases
por: Angeletti, Andrea, et al.
Publicado: (2017)

Immunological Dynamics Associated with Direct-Acting Antiviral Therapies in Naive and Experimented HCV Chronic-Infected Patients
por: Pereira, Grenda Leite, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vnit24f1tsais45ei4jgln1q6a